Seattle Genetics to Acquire Cascadian Therapeutics for $614M

Seattle Genetics plans to acquire Cascadian Therapeutics for approximately $614 million, the companies said today, in a deal that will add to the buyer’s oncology pipeline with a breast cancer candidate now under study in a pivotal Phase II trial.That candidate—Cascadian’s lead candidate—is tucatinib (ONT-380), an oral small molecule tyrosine kinase inhibitor (TKI) that is highly selective for HER2 without significant inhibition of EGFR. Tucatinib is the subject of the ra